Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats
Administration of interleukin-15 (IL-15) to rats bearing the Yoshida AH-130 ascites hepatoma (a tumour that induces an important cachectic response) resulted in a significant reduction of muscle wasting, both measured as muscle weight and as protein content of different types of skeletal muscle. In...
Gespeichert in:
| Veröffentlicht in: | FEBS letters 2004-07, Vol.569 (1-3), p.201-206 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 206 |
|---|---|
| container_issue | 1-3 |
| container_start_page | 201 |
| container_title | FEBS letters |
| container_volume | 569 |
| creator | Figueras, Maite Busquets, Sı́lvia Carbó, Neus Barreiro, Esther Almendro, Vanessa Argilés, Josep M López-Soriano, Francisco J |
| description | Administration of interleukin-15 (IL-15) to rats bearing the Yoshida AH-130 ascites hepatoma (a tumour that induces an important cachectic response) resulted in a significant reduction of muscle wasting, both measured as muscle weight and as protein content of different types of skeletal muscle. In addition, the administration of the cytokine completely reversed the increased DNA fragmentation observed in skeletal muscle of tumour-bearing animals. Concerning the mechanism(s) involved in the anti-apoptotic effects of IL-15 on skeletal muscle, the administration of the cytokine resulted in a considerable decrease in both R1 (43%) and R2 (64%) TNF-α receptors (TNFRs), and therefore it may be suggested that IL-15 decreases apoptosis by affecting TNF-α signalling. Formation of NO could be the signalling event associated with the activation of apoptosis in muscle of tumour-bearing rats; indeed, administration of IL-15 decreased the inducible nitric oxide synthase protein levels by 73%, suggesting that NO formation and muscle apoptosis during tumour growth are related. In conclusion, IL-15 seems to be able to reduce/suppress protein loss and apoptosis related to muscle wasting during cancer cachexia in experimental animals. |
| doi_str_mv | 10.1016/j.febslet.2004.05.066 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66662524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014579304007021</els_id><sourcerecordid>20505497</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5041-6a73e15e30c084bf25c2c60dbc838e58cd8736f53469ac6d478283fc4592719a3</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhiMEokvhJ4B84pZ07NhOckKl9Euq4ACcLceZtF7ysXicLv33ONqVOBZfLHve9_WMnyx7z6HgwPXZtuixpQFjIQBkAaoArV9kG15XZV5KXb_MNgBc5qpqypPsDdEW0rnmzevshCshlC7lJvtzO0UMAy6__JRzxTwx2w7I4sxo2e0CErH4gMxPLqAl7NiXr-esD_Z-xCna6OeJWaLZeRtTce_jAxsXcilibyn66T5ZWVzGeQl5izasN8FGepu96u1A-O64n2Y_ry5_XNzkd9-uby_O73KnQPJc26pErrAEB7Vse6GccBq61tVljap2XZpX9ypN3FinO1nVoi57J1UjKt7Y8jT7eMjdhfn3ghTN6MnhMNgJ54WMTksoIZ8VClCgZFMloToIXZiJAvZmF_xow5PhYFY2ZmuObMzKxoAyiU3yfTg-sLQjdv9cRxhJcHMQ7P2AT_-Xaq4uP4vvK-iVM0iACgRPUZ8OUZi-9tFjMOQ8Tg47H9BF083-mW7_AvAeuMs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20505497</pqid></control><display><type>article</type><title>Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Figueras, Maite ; Busquets, Sı́lvia ; Carbó, Neus ; Barreiro, Esther ; Almendro, Vanessa ; Argilés, Josep M ; López-Soriano, Francisco J</creator><creatorcontrib>Figueras, Maite ; Busquets, Sı́lvia ; Carbó, Neus ; Barreiro, Esther ; Almendro, Vanessa ; Argilés, Josep M ; López-Soriano, Francisco J</creatorcontrib><description>Administration of interleukin-15 (IL-15) to rats bearing the Yoshida AH-130 ascites hepatoma (a tumour that induces an important cachectic response) resulted in a significant reduction of muscle wasting, both measured as muscle weight and as protein content of different types of skeletal muscle. In addition, the administration of the cytokine completely reversed the increased DNA fragmentation observed in skeletal muscle of tumour-bearing animals. Concerning the mechanism(s) involved in the anti-apoptotic effects of IL-15 on skeletal muscle, the administration of the cytokine resulted in a considerable decrease in both R1 (43%) and R2 (64%) TNF-α receptors (TNFRs), and therefore it may be suggested that IL-15 decreases apoptosis by affecting TNF-α signalling. Formation of NO could be the signalling event associated with the activation of apoptosis in muscle of tumour-bearing rats; indeed, administration of IL-15 decreased the inducible nitric oxide synthase protein levels by 73%, suggesting that NO formation and muscle apoptosis during tumour growth are related. In conclusion, IL-15 seems to be able to reduce/suppress protein loss and apoptosis related to muscle wasting during cancer cachexia in experimental animals.</description><identifier>ISSN: 0014-5793</identifier><identifier>EISSN: 1873-3468</identifier><identifier>DOI: 10.1016/j.febslet.2004.05.066</identifier><identifier>PMID: 15225634</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Animals ; Antigens, CD - genetics ; Apoptosis ; Apoptosis - drug effects ; Base Sequence ; Body Weight - drug effects ; Cachexia - etiology ; Cachexia - pathology ; Cachexia - prevention & control ; Carcinoma, Hepatocellular - physiopathology ; Disease Models, Animal ; DNA Primers ; Gene Expression Regulation, Neoplastic - drug effects ; Humans ; Interleukin-15 ; Interleukin-15 - therapeutic use ; Male ; Muscle, Skeletal - drug effects ; Muscle, Skeletal - pathology ; Nitric oxide synthase ; Organ Size - drug effects ; Rats ; Rats, Wistar ; Receptors, Tumor Necrosis Factor - genetics ; Receptors, Tumor Necrosis Factor, Type I ; Receptors, Tumor Necrosis Factor, Type II ; Recombinant Proteins - therapeutic use ; RNA, Messenger - genetics ; Sarcoma, Experimental - physiopathology ; Skeletal muscle ; Tumour necrosis factor-α</subject><ispartof>FEBS letters, 2004-07, Vol.569 (1-3), p.201-206</ispartof><rights>2004 Federation of European Biochemical Societies</rights><rights>FEBS Letters 569 (2004) 1873-3468 © 2015 Federation of European Biochemical Societies</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5041-6a73e15e30c084bf25c2c60dbc838e58cd8736f53469ac6d478283fc4592719a3</citedby><cites>FETCH-LOGICAL-c5041-6a73e15e30c084bf25c2c60dbc838e58cd8736f53469ac6d478283fc4592719a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1016%2Fj.febslet.2004.05.066$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.febslet.2004.05.066$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,1433,3550,27924,27925,45574,45575,45995,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15225634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Figueras, Maite</creatorcontrib><creatorcontrib>Busquets, Sı́lvia</creatorcontrib><creatorcontrib>Carbó, Neus</creatorcontrib><creatorcontrib>Barreiro, Esther</creatorcontrib><creatorcontrib>Almendro, Vanessa</creatorcontrib><creatorcontrib>Argilés, Josep M</creatorcontrib><creatorcontrib>López-Soriano, Francisco J</creatorcontrib><title>Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats</title><title>FEBS letters</title><addtitle>FEBS Lett</addtitle><description>Administration of interleukin-15 (IL-15) to rats bearing the Yoshida AH-130 ascites hepatoma (a tumour that induces an important cachectic response) resulted in a significant reduction of muscle wasting, both measured as muscle weight and as protein content of different types of skeletal muscle. In addition, the administration of the cytokine completely reversed the increased DNA fragmentation observed in skeletal muscle of tumour-bearing animals. Concerning the mechanism(s) involved in the anti-apoptotic effects of IL-15 on skeletal muscle, the administration of the cytokine resulted in a considerable decrease in both R1 (43%) and R2 (64%) TNF-α receptors (TNFRs), and therefore it may be suggested that IL-15 decreases apoptosis by affecting TNF-α signalling. Formation of NO could be the signalling event associated with the activation of apoptosis in muscle of tumour-bearing rats; indeed, administration of IL-15 decreased the inducible nitric oxide synthase protein levels by 73%, suggesting that NO formation and muscle apoptosis during tumour growth are related. In conclusion, IL-15 seems to be able to reduce/suppress protein loss and apoptosis related to muscle wasting during cancer cachexia in experimental animals.</description><subject>Animals</subject><subject>Antigens, CD - genetics</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Base Sequence</subject><subject>Body Weight - drug effects</subject><subject>Cachexia - etiology</subject><subject>Cachexia - pathology</subject><subject>Cachexia - prevention & control</subject><subject>Carcinoma, Hepatocellular - physiopathology</subject><subject>Disease Models, Animal</subject><subject>DNA Primers</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Humans</subject><subject>Interleukin-15</subject><subject>Interleukin-15 - therapeutic use</subject><subject>Male</subject><subject>Muscle, Skeletal - drug effects</subject><subject>Muscle, Skeletal - pathology</subject><subject>Nitric oxide synthase</subject><subject>Organ Size - drug effects</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors, Tumor Necrosis Factor - genetics</subject><subject>Receptors, Tumor Necrosis Factor, Type I</subject><subject>Receptors, Tumor Necrosis Factor, Type II</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>RNA, Messenger - genetics</subject><subject>Sarcoma, Experimental - physiopathology</subject><subject>Skeletal muscle</subject><subject>Tumour necrosis factor-α</subject><issn>0014-5793</issn><issn>1873-3468</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAQhiMEokvhJ4B84pZ07NhOckKl9Euq4ACcLceZtF7ysXicLv33ONqVOBZfLHve9_WMnyx7z6HgwPXZtuixpQFjIQBkAaoArV9kG15XZV5KXb_MNgBc5qpqypPsDdEW0rnmzevshCshlC7lJvtzO0UMAy6__JRzxTwx2w7I4sxo2e0CErH4gMxPLqAl7NiXr-esD_Z-xCna6OeJWaLZeRtTce_jAxsXcilibyn66T5ZWVzGeQl5izasN8FGepu96u1A-O64n2Y_ry5_XNzkd9-uby_O73KnQPJc26pErrAEB7Vse6GccBq61tVljap2XZpX9ypN3FinO1nVoi57J1UjKt7Y8jT7eMjdhfn3ghTN6MnhMNgJ54WMTksoIZ8VClCgZFMloToIXZiJAvZmF_xow5PhYFY2ZmuObMzKxoAyiU3yfTg-sLQjdv9cRxhJcHMQ7P2AT_-Xaq4uP4vvK-iVM0iACgRPUZ8OUZi-9tFjMOQ8Tg47H9BF083-mW7_AvAeuMs</recordid><startdate>20040702</startdate><enddate>20040702</enddate><creator>Figueras, Maite</creator><creator>Busquets, Sı́lvia</creator><creator>Carbó, Neus</creator><creator>Barreiro, Esther</creator><creator>Almendro, Vanessa</creator><creator>Argilés, Josep M</creator><creator>López-Soriano, Francisco J</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20040702</creationdate><title>Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats</title><author>Figueras, Maite ; Busquets, Sı́lvia ; Carbó, Neus ; Barreiro, Esther ; Almendro, Vanessa ; Argilés, Josep M ; López-Soriano, Francisco J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5041-6a73e15e30c084bf25c2c60dbc838e58cd8736f53469ac6d478283fc4592719a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antigens, CD - genetics</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Base Sequence</topic><topic>Body Weight - drug effects</topic><topic>Cachexia - etiology</topic><topic>Cachexia - pathology</topic><topic>Cachexia - prevention & control</topic><topic>Carcinoma, Hepatocellular - physiopathology</topic><topic>Disease Models, Animal</topic><topic>DNA Primers</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Humans</topic><topic>Interleukin-15</topic><topic>Interleukin-15 - therapeutic use</topic><topic>Male</topic><topic>Muscle, Skeletal - drug effects</topic><topic>Muscle, Skeletal - pathology</topic><topic>Nitric oxide synthase</topic><topic>Organ Size - drug effects</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors, Tumor Necrosis Factor - genetics</topic><topic>Receptors, Tumor Necrosis Factor, Type I</topic><topic>Receptors, Tumor Necrosis Factor, Type II</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>RNA, Messenger - genetics</topic><topic>Sarcoma, Experimental - physiopathology</topic><topic>Skeletal muscle</topic><topic>Tumour necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Figueras, Maite</creatorcontrib><creatorcontrib>Busquets, Sı́lvia</creatorcontrib><creatorcontrib>Carbó, Neus</creatorcontrib><creatorcontrib>Barreiro, Esther</creatorcontrib><creatorcontrib>Almendro, Vanessa</creatorcontrib><creatorcontrib>Argilés, Josep M</creatorcontrib><creatorcontrib>López-Soriano, Francisco J</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>FEBS letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Figueras, Maite</au><au>Busquets, Sı́lvia</au><au>Carbó, Neus</au><au>Barreiro, Esther</au><au>Almendro, Vanessa</au><au>Argilés, Josep M</au><au>López-Soriano, Francisco J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats</atitle><jtitle>FEBS letters</jtitle><addtitle>FEBS Lett</addtitle><date>2004-07-02</date><risdate>2004</risdate><volume>569</volume><issue>1-3</issue><spage>201</spage><epage>206</epage><pages>201-206</pages><issn>0014-5793</issn><eissn>1873-3468</eissn><abstract>Administration of interleukin-15 (IL-15) to rats bearing the Yoshida AH-130 ascites hepatoma (a tumour that induces an important cachectic response) resulted in a significant reduction of muscle wasting, both measured as muscle weight and as protein content of different types of skeletal muscle. In addition, the administration of the cytokine completely reversed the increased DNA fragmentation observed in skeletal muscle of tumour-bearing animals. Concerning the mechanism(s) involved in the anti-apoptotic effects of IL-15 on skeletal muscle, the administration of the cytokine resulted in a considerable decrease in both R1 (43%) and R2 (64%) TNF-α receptors (TNFRs), and therefore it may be suggested that IL-15 decreases apoptosis by affecting TNF-α signalling. Formation of NO could be the signalling event associated with the activation of apoptosis in muscle of tumour-bearing rats; indeed, administration of IL-15 decreased the inducible nitric oxide synthase protein levels by 73%, suggesting that NO formation and muscle apoptosis during tumour growth are related. In conclusion, IL-15 seems to be able to reduce/suppress protein loss and apoptosis related to muscle wasting during cancer cachexia in experimental animals.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>15225634</pmid><doi>10.1016/j.febslet.2004.05.066</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-5793 |
| ispartof | FEBS letters, 2004-07, Vol.569 (1-3), p.201-206 |
| issn | 0014-5793 1873-3468 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66662524 |
| source | MEDLINE; Access via Wiley Online Library; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | Animals Antigens, CD - genetics Apoptosis Apoptosis - drug effects Base Sequence Body Weight - drug effects Cachexia - etiology Cachexia - pathology Cachexia - prevention & control Carcinoma, Hepatocellular - physiopathology Disease Models, Animal DNA Primers Gene Expression Regulation, Neoplastic - drug effects Humans Interleukin-15 Interleukin-15 - therapeutic use Male Muscle, Skeletal - drug effects Muscle, Skeletal - pathology Nitric oxide synthase Organ Size - drug effects Rats Rats, Wistar Receptors, Tumor Necrosis Factor - genetics Receptors, Tumor Necrosis Factor, Type I Receptors, Tumor Necrosis Factor, Type II Recombinant Proteins - therapeutic use RNA, Messenger - genetics Sarcoma, Experimental - physiopathology Skeletal muscle Tumour necrosis factor-α |
| title | Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A16%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-15%20is%20able%20to%20suppress%20the%20increased%20DNA%20fragmentation%20associated%20with%20muscle%20wasting%20in%20tumour-bearing%20rats&rft.jtitle=FEBS%20letters&rft.au=Figueras,%20Maite&rft.date=2004-07-02&rft.volume=569&rft.issue=1-3&rft.spage=201&rft.epage=206&rft.pages=201-206&rft.issn=0014-5793&rft.eissn=1873-3468&rft_id=info:doi/10.1016/j.febslet.2004.05.066&rft_dat=%3Cproquest_cross%3E20505497%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20505497&rft_id=info:pmid/15225634&rft_els_id=S0014579304007021&rfr_iscdi=true |